Drug
Pamrevlumab clinical trials
Also written FG-3019.
How studies write it
Studies that test it under each name
Name
Development codes
- FG-3019
- 17
Studies by the year they started
19 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 2
FibroGen (17) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Jonsson Comprehensive Cancer Center (1)
Studies
Open first, then newest update. How each study uses pamrevlumab is read from its arms, and is right about nine times in ten.
Testing it · 19
- Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic CancerCompletedPhase 3FibroGenNCT03941093Written as Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
- Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedPhase 3FibroGenNCT03955146Written as Pamrevlumab
- Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)TerminatedPhase 2FibroGenNCT02606136Written as Pamrevlumab
- Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMDTerminatedPhase 3FibroGenNCT04632940Written as Pamrevlumab
- Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedPhase 3FibroGenNCT04419558Written as Pamrevlumab
- Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)TerminatedPhase 3FibroGenNCT04371666Written as Pamrevlumab
- Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary FibrosisCompletedPhase 1FibroGenNCT00074698Written as FG-3019
- A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic CancerCompletedPhase 1/2FibroGenNCT02210559Written as FG-3019
- Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 DiseaseTerminatedPhase 2FibroGenNCT04432298Written as Pamrevlumab
- An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19CompletedPhase 2/3Fondazione Policlinico Universitario Agostino Gemelli IRCCSNCT05262309Written as Pamrevlumab
- Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedPhase 2FibroGenNCT01890265Written as Pamrevlumab
- Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary FibrosisCompletedPhase 2FibroGenNCT01262001Written as FG-3019
- Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic NephropathyCompletedPhase 1FibroGenNCT00754143Written as FG-3019
- Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)TerminatedPhase 1FibroGenNCT00782561Written as FG-3019
- Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB TherapyTerminatedPhase 2FibroGenNCT00913393Written as FG-3019
- Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic CancerWithdrawnNot applicableJonsson Comprehensive Cancer CenterNCT02851381Written as FG-3019
- A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B InfectionTerminatedPhase 2FibroGenNCT01217632Written as FG-3019
- A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic CancerCompletedPhase 1FibroGenNCT01181245Written as FG-3019
- Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes MellitusCompletedPhase 1FibroGenNCT00102297Written as FG-3019
Codes
What other systems call pamrevlumab · ClinicalTrials.gg INT005876
- MeSH (NLM) C560078pamrevlumabOne source NLM
- UNII (FDA) QS5F6VTS0OPAMREVLUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q48851069pamrevlumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C92577PamrevlumabOne source FDA
- DrugBank DB14952One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C560078 | pamrevlumab | One source NLM |
| UNII (FDA) | QS5F6VTS0O | PAMREVLUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q48851069 | pamrevlumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C92577 | Pamrevlumab | One source FDA |
| DrugBank | DB14952 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.